Literature DB >> 12654682

Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis.

Adela G de la Campa1, María-José Ferrandiz, Fe Tubau, Román Pallarés, Federico Manresa, Josefina Liñares.   

Abstract

Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy. One ciprofloxacin-susceptible strain was isolated before treatment, and four ciprofloxacin-resistant strains were isolated during treatment. The resistant strains were derived from the susceptible strain either by a parC mutation (low-level resistance) or by parC and gyrA mutations (high-level resistance). This study shows that ciprofloxacin therapy in a patient colonized by susceptible S. pneumoniae may select fluoroquinolone-resistant mutants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654682      PMCID: PMC152524          DOI: 10.1128/AAC.47.4.1419-1422.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients.

Authors:  M Venditti; P Baiocchi; C Santini; C Brandimarte; P Serra; G Gentile; C Girmenia; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.

Authors:  R Muñoz; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s.

Authors:  S Soares; K G Kristinsson; J M Musser; A Tomasz
Journal:  J Infect Dis       Date:  1993-07       Impact factor: 5.226

6.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

7.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

Authors:  J Tankovic; B Perichon; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections.

Authors:  Roman Pallares; Olga Capdevila; Josefina Liñares; Imma Grau; Hisao Onaga; Fe Tubau; Marco H Schulze; Peter Hohl; Francesc Gudiol
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

9.  Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

Authors:  R Pallares; J Liñares; M Vadillo; C Cabellos; F Manresa; P F Viladrich; R Martin; F Gudiol
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

10.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.

Authors:  J Hofmann; M S Cetron; M M Farley; W S Baughman; R R Facklam; J A Elliott; K A Deaver; R F Breiman
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

View more
  10 in total

1.  Pneumococci can persistently colonize adult patients with chronic respiratory disease.

Authors:  A Domenech; C Ardanuy; L Balsalobre; S Marti; L Calatayud; A G De la Campa; A B Brueggemann; J Liñares
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

2.  Clonal spread of levofloxacin-resistant streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009.

Authors:  Iciar Rodríguez-Avial; Belén Ramos; Esther Ríos; Emilia Cercenado; María Ordobás; Juan Carlos Sanz
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

3.  Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.

Authors:  Luz Balsalobre; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

4.  Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae and molecular characterization of multidrug-resistant serotype 19F, 6B, and 23F Pneumococci in northern Thailand.

Authors:  Hiroshi Watanabe; Norichika Asoh; Kazuhiko Hoshino; Kiwao Watanabe; Kazunori Oishi; Weerayut Kositsakulchai; Tippaya Sanchai; Khemrassamee Kunsuikmengrai; Sumpun Kahintapong; Banyong Khantawa; Prasit Tharavichitkul; Thira Sirisanthana; Tsuyoshi Nagatake
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

5.  Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.

Authors:  Adela G de la Campa; Luz Balsalobre; Carmen Ardanuy; Asunción Fenoll; Emilio Pérez-Trallero; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

Review 6.  Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones.

Authors:  J Mensa; A Trilla
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

7.  Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

Authors:  Adela G de la Campa; Carmen Ardanuy; Luz Balsalobre; Emilio Pérez-Trallero; Jose M Marimón; Asunción Fenoll; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

8.  Some pneumococcal serotypes are more frequently associated with relapses of acute exacerbations in COPD patients.

Authors:  Arnau Domenech; Carmen Ardanuy; Roman Pallares; Immaculada Grau; Salud Santos; Adela G De la Campa; Josefina Liñares
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

9.  Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.

Authors:  Emilio Pérez-Trallero; José M Marimon; Luis Iglesias; Julián Larruskain
Journal:  Emerg Infect Dis       Date:  2003-09       Impact factor: 6.883

10.  Technetium-99m Tricarbonyl Labeled a Broad-spectrum Quinolone as a Specific Imaging Agent in Infection Diseases.

Authors:  Seyed Javad Khoramrouz; Mostafa Erfani; Mitra Athari Allaf
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.